Perioperative Analgesia Modes in Minimally Invasive Esophagectomy

• Status: Not yet recruiting
• Trial end date: 2023-05-20
• Target enrollment: 0
• Participant gender: All

Summary

This study was designed to compare analgesic efficacy and safety of different perioperative analgesic modes in minimally invasive esophagectomy for esophageal cancer.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Treatments: Flurbiprofen; Flurbiprofen axetil

Criteria

Inclusion Criteria:

• 18-75 years;

• Patients underwent laparoscopic and thoracoscopic or robotic-assisted minimally invasive esophagectomy ;

• Informed consent.

Exclusion Criteria:

• Has a history of cholecystitis or urolithiasis within 3 months;

• Has a history of atherothrombosis (peripheral arterial disease), stroke, myocardial infarction;

• With lung diseases, such as pneumonia, atelectasis, emphysema, pulmonary bullae, etc;

• Preoperative cardiac function grade ≥ III or coronary artery stenosis;

• Preoperative indwelling of a thoracic drainage tube;

• Long-term heavy drinker(heavy drinking was defined as follows: for men, consuming more than 4 drinks on any day or more than 14 drinks per week; For women, consuming more than 3 drinks on any day or more than 7 drinks per week);

• Opioid-tolerant patients(defined as those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid);

• With painful skin complications, such as rashes and blisters;

• Conversion to open surgery;

• The postoperative ventilation function was limited, or the duration of endotracheal intubation was more than 24h.